August 2023: As part of our work to make our guidance more useful and usable, we are testing out some changes to improve the way we present our guidance.
The recommendations from the technology appraisal guidance on nab-paclitaxel with gemcitabine (TA476) have been brought into this guideline.
This is so that healthcare professionals can see our recommendations for this medicine quickly, at the right point in this guideline and without having to click onto another page.
This is something we are testing with our users at the moment. It is not the final presentation. Tell us what you think using our survey, or if you have any questions, contact us at email@example.com.
January 2022: Minor change to redirect NICE Pathway link.